The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …

Since the discovery of the JAK 2 V617F mutation in the majority of the myeloproliferative
neoplasms (MPN) of polycythemia vera, essential thrombocythemia and primary …

Myeloproliferative neoplasms (MPNs) are a group of clonal disorders characterized by
aberrant hematopoietic proliferation and an increased tendency toward leukemic …

Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are
refractory, have a suboptimal response, or quickly lose their response. To identify genes that …

RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is
limited data on the significance of RAS-pathway mutations in patients with myelofibrosis …

The distinction between chronic eosinophilic leukemia, not otherwise specified and
idiopathic hypereosinophilic syndrome largely relies on clonality assessment. Prior to the …

To address the clinical relevance of small DNA variants in chronic myeloid neoplasms
(CMNs), an Association for Molecular Pathology Working Group comprehensively reviewed …

Molecular routine diagnostics for BCR‐ABL 1‐negative myeloproliferative neoplasms (MPN)
currently focusses on mutations in JAK 2, CALR and MPL. In recent years, recurrent …

For nearly two decades most research on BARD1 was closely linked to research on BRCA1,
the breast cancer predisposition gene. The co-expression of BARD1 and BRCA1 genes in …

Recent advances in DNA sequencing technologies have enhanced our knowledge about
several diseases. Coupled with easy accessibility to blood samples, hematology plays a …